Syndax Pharmaceuticals Obtains $9,000,000 New Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=57d11f21-be06-4f36-8f3a-2018059d2eb5&Preview=1 - Date
2/3/2010 - Company Name
Syndax Pharmaceuticals - Mailing Address
460 Totten Pond Road Waltham, MA 02451 - Company Description
Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused biotechnology company that is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company’s intellectual property is based on work from scientific founder Ronald Evans, Ph.D., recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator. - Website
http://www.syndax.com - Transaction Type
Venture Equity - Transaction Amount
$9,000,000 - Transaction Round
Undisclosed - Proceeds Purposes
Proceeds purposes were not disclosed. - M&A Terms
- Venture Investor
Domain Associates - Venture Investor
MPM Capital
